Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAT8881 in Neuropathic Pain
NCT03865953Phase 2Completed
- Sponsor
- Lateral Pharma
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of LAT8881 in neuropathic pain, diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN) (2 arms), sponsored by Lateral Pharma. Primary endpoint: Absolute Change in Mean Pain Score, Using an 11 Point Numeric Pain Rating Scale (NPRS) at 4 weeks. Started Apr 2019; status: completed.
02
Drugs
LAT8881
03
Conditions
neuropathic paindiabetic peripheral neuropathy (DPN)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT03865953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865953.